China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?
Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.